Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.
作者信息
Liuzzo Giovanna, Patrono Carlo
机构信息
Associate Professor of Cardiology Catholic University, Largo A. Gemelli Rome, Italy.
Adjunct Professor of Pharmacology Catholic University School of Medicine Rome, Italy and Perelman School of Medicine University of Pennsylvania Philadelphia, USA.
出版信息
Eur Heart J. 2021 Mar 1;42(9):882-883. doi: 10.1093/eurheartj/ehab043.
Abstract
摘要
相似文献
1
Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.在新冠疫情中无明确用途而重新启用的抗病毒药物：给临床医生的宝贵教训
Eur Heart J. 2021 Mar 1;42(9):882-883. doi: 10.1093/eurheartj/ehab043.
2
Repurposing drugs during the COVID-19 pandemic and beyond.在新冠疫情期间及之后对药物进行重新利用。
Pharm Pat Anal. 2021 Jan;10(1):9-12. doi: 10.4155/ppa-2020-0031. Epub 2021 Jan 15.
3
Old and re-purposed drugs for the treatment of COVID-19.用于治疗 COVID-19 的老药和再利用药物。
Expert Rev Anti Infect Ther. 2020 Sep;18(9):843-847. doi: 10.1080/14787210.2020.1771181. Epub 2020 Jun 1.
4
Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?多发性硬化症中干扰素-β的三十年：我们能否将这些信息用于治疗新型冠状病毒2感染？
Front Immunol. 2020 Jun 18;11:1459. doi: 10.3389/fimmu.2020.01459. eCollection 2020.
5
Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.重新定位药物以应对 COVID-19 大流行——一个洞察。
Curr Pharm Biotechnol. 2021;22(2):192-199. doi: 10.2174/1389201021999200820155927.
6
Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.肺病网络揭示了合并症对 SARS-CoV-2 感染的影响和药物再利用的机会。
BMC Med Genomics. 2021 Sep 17;14(1):226. doi: 10.1186/s12920-021-01079-7.
7
Investigational antiviral drugs for the treatment of COVID-19 patients.用于治疗 COVID-19 患者的抗病毒药物研究。
Arch Virol. 2022 Mar;167(3):751-805. doi: 10.1007/s00705-022-05368-z. Epub 2022 Feb 9.
8
Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak.重新定位和传统药物治疗 COVID-19 大流行的最新方法。
Mini Rev Med Chem. 2021;21(8):952-968. doi: 10.2174/1389557520666201124141103.
9
Repurposing antimalarials and other drugs for COVID-19.将抗疟药及其他药物重新用于治疗新冠肺炎。
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
10
Potential drug development and therapeutic approaches for clinical intervention in COVID-19.针对 COVID-19 的临床干预的潜在药物研发和治疗方法。
Bioorg Chem. 2021 Sep;114:105016. doi: 10.1016/j.bioorg.2021.105016. Epub 2021 May 25.
引用本文的文献
1
Targeting mutation sites in the omicron variant of SARS-CoV-2 as potential therapeutic strategy against COVID-19 by antiretroviral drugs.以严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变异株中的突变位点为靶点，采用抗逆转录病毒药物作为对抗2019冠状病毒病（COVID-19）的潜在治疗策略。
Toxicol Rep. 2024 Nov 22;13:101825. doi: 10.1016/j.toxrep.2024.101825. eCollection 2024 Dec.
2
Cardiovascular consequences of viral infections: from COVID to other viral diseases.病毒感染的心血管后果：从 COVID 到其他病毒疾病。
Cardiovasc Res. 2021 Nov 22;117(13):2610-2623. doi: 10.1093/cvr/cvab315.
3
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.羟乙胺类似物的抗病毒评估：针对 SARS-CoV-2 主蛋白酶（3CLpro）的抑制剂，一种虚拟筛选和模拟方法。
Bioorg Med Chem. 2021 Oct 1;47:116393. doi: 10.1016/j.bmc.2021.116393. Epub 2021 Sep 4.
Zotero 插件